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Abstract The contribution of deficient telomerase
activity to age-related decline in osteoblast functions
and bone formation is poorly studied. We have
previously demonstrated that telomerase over-expres-
sion led to enhanced osteoblast differentiation of
human bone marrow skeletal (stromal) stem cells
(hMSC) in vitro and in vivo. Here, we investigated the
signaling pathways underlying the regulatory func-
tions of telomerase in osteoblastic cells. Comparative
microarray analysis and Western blot analysis of
telomerase-over expressing hMSC (hMSC-TERT)
versus primary hMSC revealed significant up-regula-
tion of several components of insulin-like growth
factor (IGF) signaling. Specifically, a significant
increase in IGF-induced AKT phosphorylation and
alkaline phosphatase (ALP) activity were observed in
hMSC-TERT. Enhanced ALP activity was reduced in
presence of IGF1 receptor inhibitor: picropodophyllin.
In addition, telomerase deficiency caused significant
reduction in IGF signaling proteins in osteoblastic
cells cultured from telomerase deficient mice
(Terc-/-). The low bone mass exhibited by Terc-/-
mice was associated with significant reduction in
serum levels of IGF1 and IGFBP3 as well as reduced
skeletal mRNA expression of Igf1, Igf2, Igf2r, Igfbp5
and Igfbp6. IGF1-induced osteoblast differentiation
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was also impaired in Terc-/-MSC. In conclusion, our
data demonstrate that impaired IGF/AKT signaling
contributes to the observed decreased bone mass and
bone formation exhibited by telomerase deficient
osteoblastic cells.
Keywords Telomerase  Bone marrow stromal stem
cells  Osteoblasts  Bone  Aging  IGF
Introduction
Osteoblast dysfunction is the main determinant of age-
related decline in bone formation and bone loss (Kassem
and Marie 2011). Several extrinsic factors contribute to
age-related impairment in osteoblastic functions such as
age-related decline in the levels of trophic hormones e.g.
estrogen, growth hormone or increased oxidative stress
(Almeida et al. 2007; Ernst et al. 1989;Khosla andRiggs
2005; Kveiborg et al. 2000; Manolagas 2010; Boonen
et al. 1999).On the other hand, cell intrinsic deficiency in
telomerase activity leading to telomere shortening and
cellular senescence contributes to organismal aging (Ye
et al. 2014). There is increasing evidence that telomerase
deficiency and telomere shortening contribute to the
in vivo age-related impairment in bone formation. We
have previously demonstrated that the telomerase defi-
cient mice (Terc-/-) exhibited impaired in vivo
osteoblastic bone formation and reduction in bone mass
(Saeed et al. 2011) caused by cell autonomous impair-
ment of osteoblastic cells of Terc-/-mice. On the other
hand, telomerase activation either through pharmaco-
logical intervention (deBernardes et al. 2011) or through
gene therapy (de Bernardes et al. 2012) led to improve-
ment in several age-related changes in mice including
some increase in bonemass.At a cellular level, enhanced
telomerase activity by over-expressing human telom-
erase reverse transcriptase (hTERT) gene in human bone
marrow-derived stromal (skeletal) stem cells (hMSC)
resulted in enhanced in vitro osteoblast differentiation
and in vivo heterotopic bone formation (Abdallah et al.
2005; Simonsen et al. 2002).
Little is known about the regulatory mechanisms
underlying the effects of telomerase activity and
telomere length on osteoblast differentiation. Insulin-
like growth factor 1 (IGF1) is one of the important bone
anabolic factors. Skeletal IGF1 expression is reduced
during aging and its levels are correlated with age-
related reduction in bone mass (Liu et al. 2008; Yakar
et al. 2002). The IGF system includes two ligands IGF1
and IGF2 interacting with IGF1 cognate receptor
(IGFR1) and a number of IGF binding proteins
(IGFBPs) (Conover 2008). IGF system has been
demonstrated to regulate MSC proliferation (Langdahl
et al. 1998) and osteoblast differentiation and functions
(Xue et al. 2013). Several signaling pathways mediate
the effects of IGFs on bone (Giustina et al. 2008).
Among these, IGF1 induction of PI3K/AKT pathway is
a principal regulator of osteoblast functions (Fujita et al.
2004; Levine et al. 2006; Raucci et al. 2008; Liu et al.
2007). PI3Ks are heterodimers consisting of two
subunits, catalytic subunit p110 and regulatory unit
p85. PI3Ks are activated by either receptor protein
tyrosine kinase (RPTK) or G-protein coupled receptors
(Fresno Vara et al. 2004). This activation results in the
recruitment of several proteins with pleckstrin homol-
ogy domain (PH) including PDK1 and AKT. The
activation of AKT plays an important role in regulating
osteoblast proliferation, differentiation and survival
both in vitro and in vivo (Ghosh-Choudhury et al. 2002;
Kawamura et al. 2007; Kawamura and Kawaguchi
2007; Mukherjee and Rotwein 2009). Interestingly, the
effects of telomerase activity on several biological
processes, such as, cell growth, cell cycle and apoptosis
have been reported to be mediated via PI3K/AKT
pathway (Xia et al. 2008; Kang et al. 1999). Also, AKT
has been implicated in IGF1 driven telomerase activity
in a multiple myeloma cell line (Akiyama et al. 2002).
In the present study, we examined whether IGF
signaling mediates the biological effects of telomerase
activity on osteoblastic cell differentiation and func-
tions. We studied the effects of genetic gain and loss of
telomerase functions in MSC on IGF/AKT expression
and activation. We demonstrated that telomerase
activation in MSC resulted in the up-regulation of
IGF/IGFBPs system and IGF-induced AKT signaling.
In addition, telomerase-deficiency-induced bone loss
in mice was associated with reduced expression and
serum levels of IGF and IGFBPs along with impaired
IGF-induced AKT activation in MSC.
Materials and methods
Cell culture and reagents
Mouse bone marrow cells were isolated and cultured
according to the protocol described by Peister et al.
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(Peister et al. 2004), with modifications (Post et al.
2008). Media was changed for every 3rd day. After
1–2 weeks, the cells were dissociated using Trypsin/
EDTA for 4 min at 37 C and plated according to the
experimental setup.
Primary hMSCs were established from bone mar-
row aspirates obtained from iliac crest from healthy
donors aged 25–30 years. Ethical approval was
granted by the local Scientific Ethical Committee.
Bone marrowmononuclear cells were isolated by low-
density gradient centrifugation using Lymphoprep
(Medinor, Copenhagen, Denmark) and hMSCs cul-
tures were established by plastic adherence as
described (Kassem et al. 1993).
Telomerase over-expressing human bone marrow
stromal cell line known as hMSC-TERT has been
established and characterized in our lab. The method
of establishing hMSC-TERT and its characterization
have been described in our previous publications
(Abdallah et al. 2005; Simonsen et al. 2002).
IGF-1R Inhibitor, Picropodophyllin (PPP) was
purchased from Santa Cruz Biotechnology, Inc, (Hei-
delberg, Germany).
DNA microarray analysis
Both primary hMSCs and hMSC-TERT cells were
cultured in triplicate at 3 9 104 cells/cm2 in petri
dishes in standard growth medium. When they were
90–100 % confluent, total cellular RNA was isolated
from each of three independent cultures using an
RNeasy Kit (QIAGEN, Valencia, CA, USA) accord-
ing to the manufacturer’s instructions. First- and
second-strand cDNA synthesis was performed from
8 lg total RNA using the SuperScript Choice System
(Life-Technologies, Carlsbad, CA, USA) according to
the manufacturer’s instructions. Subsequent
hybridization and scanning of the Affymetrix Gene-
Chip arrays were performed as described previously
(Tsugawa et al. 2003a). The biotinylated targets were
hybridized to human U133 Plus 2.0 Array Affymetrix
GeneChip oligonucleotide arrays. Expression mea-
sures were generated and normalized using the RMA
procedure (Irizarry et al. 2003; Shie et al. 2012),
implemented in the Bioconductor package (www.
bioconductor.org/). Data was analyzed using Ingenu-
ity Pathway analysis knowledge base system (Inge-
nuity Systems, www.ingenuity.com). Signaling
pathways known to play an important role in
osteoblast commitment, proliferation, differentiation
and function were identified among pathways that are
differentially up or down regulated in comparison to
control (minimum value = 2 fold).
Mice breeding, genotyping and handling
Terc deficient mice (Terc-/- Strain-004132) were
purchased from Jackson laboratory (Maine, USA) and
kept in a pathogen-free environment on standard
chow. Terc-/-mice were inter-crossed to generate 3rd
generation Terc-/- (Terc-/--G3) mice, and were
maintained in a C57BL/6J background. Wild type
(WT) mice were employed as controls. Genotyping
was performed according to the protocol recom-
mended by Jackson laboratory (Saeed et al. 2011).
Serum IGFs and IGFBPs measurements
Blood samples were collected from WT and Terc-/-
mice (n = 5) and serum was collected and frozen
down at -80 C. Serum IGF1 level was measured by
RIA using a polyclonal rabbit antibody (Nichols
Institute Diagnostics, San Capistrano, CA) and recom-
binant human IGF1 as standard (GE Healthcare, Little
Chalfont, UK). Monoiodinated IGF1 (125I-labeled
[Tyr31] IGF1) was obtained from Novo-Nordisk
(Bagsvaerd, Denmark). Serum IGFBPs were mea-
sured by Western ligand blotting assay as described
previously (Abdallah et al. 2007; Flyvbjerg et al.
1992).
RNA isolation and quantitative real time PCR
RNA was isolated from long bones and cultured cells
using Trizol method according to the manufacture’s
protocol.
cDNA was synthesized from 2 lg of total RNA
using a commercial revertAid H minus first strand
cDNA synthesis kit (Fermentas, Helsingborg, Swe-
den), according to the manual’s instructions.
Gene expression was determined by quantitative
real-time PCR (RT-PCR), performed in an iCycler IQ
detection system (Bio-Rad, Herlev, Denmark), using
IQ SYBR Green as a double strand DNA-specific
fluorescent binding dye. RT-PCR was performed in a
final volume of 20 ll, containing 3 ll cDNA (diluted
1:20), 20 pmol of each primer and 10 ll of IQ SYBR
Green Supermix (Bio-Rad, Herlev, Denmark)
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according to the manual’s instruction. Expression
level for each target gene was calculated using a
comparative Ct method [(1/(2DCt) formula and data
were represented as relative expression to Actin
reference gene. Data were analysed using Microsoft
Excel 2000 to generate relative expression values.
Osteoblast differentiation
MSCs were plated at 20 9 103 cells/cm2 in 24 well
plates and induced to differentiate into osteoblasts in
Iscove modified Dulbecco medium (IMDM; GIBCO,
Cat. No. 21980) containing 12 % FBS (FBS; GIBCO),
100 U/ml penicillin (GIBCO), 100 lg/ml streptomycin
(GIBCO) and 12 lM L-glutamine (GIBCO, Cat. No.
25030) supplemented with 10 nM dexamethasone
(Sigma), 10 mM b—glycerol-phosphate (Sigma),
50 lg/ml Vitamin C (Sigma) and 10 ng/ml IGF-1.
Media were changed every 3rd day until day 10.
Cytochemical staining
Alkaline phosphatase (ALP) enzymatic staining
Cells were fixed with acetone/citrate buffer pH 4.2
(1.5:1) for 5 min at room temperature and stained with
Napthol-AS-TR-phosphate solution for 1 h at room
temperature. Napthol-AS-TR-phosphate solution con-
sists of Napthol-AS-TR-phosphate (Sigma) diluted
1:5 in H2O and Fast Red TR (Sigma) diluted 1:1.2 in
0.1 M Tris buffer (OUH pharmacy), pH 9.0, after
which both solutions were mixed 1:1. Cells were
counterstained with Mayers-Hematoxylin for 5 min at
room temperature.
Alkaline phosphatase activity assay
ALP activity was measured by using p-nitrophenyl
phosphate (Fluka, Denmark) as substrate—normal-
ized against the cell number as described previously
(Qiu et al. 2010). Briefly, cell number was quantitated
by adding CellTiter-Blue reagent (Promega) to culture
medium, incubating at 37 C for 1 h and measuring
fluorescent intensity (560EX/590EM). Thereafter, cells
were washed with phosphate-buffered saline and Tris-
buffered saline, fixed in 3.7 % formaldehyde, 90 %
ethanol for 30 s at room temperature, incubated with
substrate (1 mg/ml of p-nitrophenyl phosphate in
50 mM NaHCO3, pH 9.6, and 1 mM MgCl2) at 37 C
for 20 min, and the absorbance was measured at
405 nm.
Western blot analysis
Cells were treated for short term with IGF-1 recom-
binant protein (R&D, systems) and collected at
different time points post treatment—washed in PBS
before adding cell lysis buffer (10 mM Tris–HCl, pH
7.4, 150 mM sodium chloride, 1 % Nonidet P-40,
0.1 % SDS, 1 mM EDTA, 1 mM phenylmethylsul-
fonyl fluoride, 1 mM NaF, 1 mM Na3VO4), supple-
mented by protease inhibitor mixture (Roche
Diagnostics, Mannheim, Germany). 30 lg of protein
was size fractionated using SDS-PAGE (Invitrogen,
Denmark) and electroblotted onto Immobilon-P mem-
brane (Millipore, Denmark). Blots were blocked by
5 % milk powder in Tris-buffered saline (TBS,
pH 8.0) for 1 h. Antibodies (total or phosphor) specific
for AKT (Ser-473), PTEN (Ser380/Ther382/383),
p85, PDK1 (Ser-2448) were obtained from Cell
Signaling Technology (Leiden, Netherlands).
Primary antibody (1:1000) incubations were per-
formed in 5 % milk powder TBST (TBS containing
0.1 % Tween 20) overnight followed by incubation
with secondary antibody (1:1000) with horseradish
peroxidase for 2 h conjugated. Proteins were visualized
with the ECL system (Amersham bioscience, UK).
Western blot band area/intensity was measured as
described previously (Tsugawa et al. 2003b). Bands
area/intensity for AKT, PDK1 and alpha-tubulin were
measured using Image J (Wayne Rasband, NIH, http://
rsb.info.nih.gov/ij) software (Chapman et al. 2006).
Statistical analysis
Statistical tests were performed using Microsoft
Excel and Graphpad5 (Prism). Pairwise compar-
isons were performed using student t test. An alpha
value B0.05 was considered statistically significant.
Results
Telomerase activation in human MSC enhanced
IGF and PI3K/AKT signaling
We have previously shown that increased telomerase
activity in hMSC by stable over-expression of hTERT
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in hMSC-TERT cell line, resulted in enhanced cell
proliferation and in vivo heterotopic bone formation
(Abdallah et al. 2005; Simonsen et al. 2002). To
identify signaling pathways mediating the stimulatory
effect of telomeraization on hMSCs biology, we
compared the molecular signature of primary hMSC
where telomerase activity is absent (Simonsen et al.
2002) and hMSC-TERT cells using Affymetrix DNA
micro-arrays (unpublished data). Ingenuity pathway
analysis of differentially up-regulated genes by
hMSC-TERT revealed significant enrichment of com-
ponents of IGF signaling (Sos2, Pik3c2A, Akt3,
Pik3c3, Igfbp4 and Igfbp2) and PI3 K/AKT signaling
(Akt3, Pik3r1, Pik3cA, Sos2, Itga4 and Eif4E)
(Fig. 1a(ii), B-C, 1SB).
Enhanced telomerase activity in hMSC increased
PI3K/AKT signaling and AKT phosphorylation
A number of studies have shown that AKT activation
promotes cell proliferation, survival and differentia-
tion in osteoblasts (Ghosh-Choudhury et al. 2002;
Kawamura et al. 2007; Kawamura and Kawaguchi
2007; Mukherjee and Rotwein, 2009). To verify the
activation of IGF signaling pathway by telomerase
activity, we studied the activation of IGF downstream
target proteins in hMSC-TERT versus primary
hMSCs. As shown in Fig. 2a, Western blot analysis
revealed a significant up-regulation of IGF-induced
AKT phosphorylation in hMSC-TERT as compared to


























































Fig. 1 Enhanced telomerase activity in human marrow stromal
cells (hMSC) Stimulates IGF/PI3K/AKT Signaling. Microarray
analysis was performed for hMSC-TERT and primary isolated
hMSC at baseline as described in the Materials and Methods.
a. (i) Gene ontology of significantly expressed genes in hMSC-
TERT in comparison to primary hMSC. (ii) Significantly up-
regulated signaling pathways as revealed by Ingenuity
pathway analysis in hMSC-TERT versus hMSC. b Components
of IGF signaling pathway that are differentially induced by
telomerase activation in hMSC. c Components of PI3K/AKT
signaling that are differentially induced by telomerase activation
in hMSC. Black bars represent up-regulated while white bars
represent down-regulated pathways in hMSC-TERT versus
hMSC. p values obtained by Fisher’s exact test and presented
as—log
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p-PDK1 after 10 min of IGF1 stimulation was also
observed (Fig. 2a). On the other hand, no detectable
significant changes were observed in PTEN protein
levels (Fig. 2a). IGF-induced osteoblast differentia-
tion was significantly enhanced in hMSC-TERT
compared to primary hMSC as assessed by increased
alkaline phosphatase (ALP) activity measurements
(Fig. 2b). To ensure that the effect on osteoblast
differentiation was specific for IGF signaling, we
examined the effect of specific IGF1R inhibitor
picropodophyllin (PPP) on IGF-induced ALP activity
in both primary hMSCs and hMSC-TERT cells. As
shown in Fig. 2c, treatment with PPP led to a dose-
dependent inhibition of IGF-induced ALP activity
with more pronounced effect in hMSC-TERT than
primary hMSC.
Telomerase deficient mice exhibited changes
in serum levels of IGF and its binding proteins
(IGFBPs)
IGF1/IGFBP3 axis has been reported to regulate bone
growth and bonemass (Schmid et al. 1991; Yakar et al.
2002). Likewise, reduced serum levels of IGF1 and
IGFBP3 have been implicated in the pathogenesis of
age-related osteoporosis (Sugimoto et al. 1997). To
study the effect of loss of telomerase activity on IGF
system, we measured serum levels of IGF1 and its
binding proteins (IGFBPs) in Terc-/- mice and WT
controls. As shown in Fig. 3a, serum IGF1 and
IGFBP3 were significantly decreased in Terc-/-mice.
Since production of IGFs in local tissue microenvi-
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hMSC-TERT Primary hMSC
Fig. 2 Enhanced telomerase activity in hMSC promotes IGF-
induced osteoblast differentiation and activation of AKT
signaling. a Enhanced telomerase activity in hMSC-TERT
increased AKT phosphorylation following IGF1 treatment.
Western blot analysis of phosphorylated and total proteins of
AKT, PTEN and PDK1 following 5, 10 and 20 min of IGF1
treatment (10 ng/ml). Quantification analysis of WB was
performed by ImageJ. b Alkaline phosphatase (ALP) activity
normalized for cell number in primary hMSC and hMSC-TERT
following treatment with IGF1 (dose range 1–100 ng/ml).
c Primary hMSC and hMSC-TERT were treated with IGF1
(100 ng/ml) in the absence or the presence of IGF1R specific
inhibitor (PPP). After 6 days of induction, ALP activity was
measured and normalized to cell number per each treatment
condition. Data are mean ± SD of three independent experi-
ments. *p B 0.05, **p B 0.01
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et al. 1999), we also measured mRNA expression of
Igf1, Igf2 and Igfbp1, Igfbp5, Igfbp6 in bone matrix.
We found that their expression was significantly
reduced in the bone matrix of Terc-/- mice (Fig. 3b).
Terc-/- mMSCs exhibits defective IGF signaling
We next examined gene expression profiles of Igf/
Igfbp system in murine MSC (mMSC) cultured from
bone marrow samples obtained from Terc-/- and WT
control mice. At baseline, Terc-/- mMSCs exhibited
reduced mRNA expression of Igf1, Igf2, Igf1receptor
(Igf1r) and higher expression of Igfbp1, Igfbp2, Igfbp4
and Igfbp6 as compared to WT mMSC (Fig. 4a).
Following in vitro osteoblast differentiation in the
presence of IGF1, the Terc-/- MSCs exhibited
impaired osteoblast differentiation in response to
IGF treatment as observed by reduced staining for
ALP (Fig. 4b) and reduced expression levels of Igf1,
Igf2, Igf1r, Igfbp1 and Igfbp6, while, expression of
Igf2r, Igfbp4 and Igfbp5 were increased (Fig. 4c).
To study the mechanism underlying the impairment
of IGF-induced osteoblast differentiation in Terc-/-
mMSCs, we treated WT mMSCs with IGF (10 ng/ml)
that resulted in increased levels of P-AKT and its
downstream target P-PDK1 (Fig. 5a). In contrast IGF-
induced AKT phosphorylation was absent in Terc-/-
mMSCs (Fig. 5a). No detectable differences in total
PTEN and P-PTEN were observed between Terc-/-
MSCs and WT-MSCs following IGF1 stimulation
(Fig. 5a).
Discussion
In the present study, we identified IGF signaling as a
downstream target of telomerase activity in skeletal
stem cells (MSC). Mice lacking telomerase activity
exhibited impaired osteoblastic functions and low
bone mass that were associated with reduction in
IGF1/IGFBP3 serum levels and impairment of IGF/
AKT signaling in MSCs. Our data suggest a link
between the absence of telomerase activity and the
impairment of IGF signaling in MSC as a contributing
factor for age-related reduced osteoblast function and
bone formation.
We have previously demonstrated, in a number of



































































Fig. 3 Telomerase deficiency in mice is associated with
changes in levels of IGFs and IGFBPs. a Serum levels of IGF-
1 and IGFBPs (IGFBP1-4) in telomerase deficient mice Terc-/-
and wild type controls. b Gene expression of Igfs (Igf-1, Igf-2,
Igf-1r and Igf-2r) and Igfbps ((IGFBP1-6) in Terc-/- tibia
compared to WT controls. Each target gene was normalized to
b-actin and represented as fold change over WT controls. Data
are mean ± SD. *p B 0.05, **p B 0.01. (n = 5)
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between telomerase activity, telomere length and
skeletal tissue homeostasis (Abdallah et al. 2005;
Simonsen et al. 2002; Saeed et al. 2011). Over-
expression of telomerase in hMSC not only extended
their life span but also enhanced their in vivo hetero-
topic bone formation capacity (Simonsen et al. 2002).
Telomerase deficiency in Terc-/- mice resulted in
age-related reduction in bone mass caused by defec-
tive osteoblast differentiation and creation of pro-
inflammatory bone marrow micro-environment favor-
ing osteoclast formation (Saeed et al. 2011). However,
the target of telomerase activity inMSCs is not known.
We observed up-regulation of IGF-related genes
including AKT phosphorylation in response to
increased telomerase activity in hMSC suggesting
the involvement of IGF/AKT signaling pathway in
mediating the telomerase functional effects. The
association between telomerase activity and PI3
K/AKT signaling pathway has previously been
reported in a number of cellular models including
growth hormone dependent telomerase activation via
PI3 K signaling in Chinese hamster ovary cells
(Gomez-Garcia et al. 2005). Also, transcriptional
activation of hTERT in human T cell leukemia—
lymphoma virus-1 infected cells was mediated by
PI3K (Bellon and Nicot 2008) and PI3K/AKT-depen-
dent activation of hTERT was reported to be accom-
plished by ectopic expression of EGFR in oral
squamous epithelial cells (Heeg et al. 2011). Finally,
increased telomerase activity in natural killer cells
after IL2 stimulus took place via PI3K/AKT signaling
(Kawauchi et al. 2005). Interestingly, a number of
studies have shown that PI3K/AKT signaling pathway
regulates hTERT activity (Breitschopf et al. 2001;
Haendeler et al. 2003; Kang et al. 1999). Thus, it is







































































Fig. 4 Inhibition of IGF1-induced osteoblast differentiation in
telomerase deficient murine marrow stromal cells (mMSCs).
a Real time PCR gene expression analysis of Igf1, Igf2, Igf1r,
Igf2r, Igfbp1, Igfbp2, Igfbp4, Igfbp5 and Igfbp6 in Terc-/-
mMSCs versus WT mMSCs at baseline. Each target gene was
normalized to b-actin and represented as fold change over WT
mMSCs. B.Alkaline phosphatase (ALP) staining at day 5 (upper
panel) and at day 10 (lower panel) following IGF-1 induced
osteoblast differentiation in Terc-/- mMSCs versus WT
mMSCs. C. Real time PCR analysis of Igfs, IGF receptors
(IGFr) and IGF binding proteins (IGFBPs) expression after
7 days of IGF-1 induction in Terc-/- mMSCs versus WT
mMSC. Each target gene was normalized to b-actin and
represented as fold change over control non-induced cells. Data
are mean ± SD. *p B 0.05, **p B 0.01. (n = 3)
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AKT signaling via a feedback mechanism during bone
formation that requires recruitment and proliferation
of MSC at bone formation sites.
We observed that serum levels of IGF1 and
IGFBP3 were reduced in telomerase deficient mice
Several human studies have reported an association
between decreased serum IGF1 and age-related
reduction in bone mass and bone strength (Bar-
rett-Connor and Goodman-Gruen 1998; Langlois
et al. 1998; Yamaguchi et al. 2006; Garnero et al.
2000; Ohlsson et al. 2011; Rosen et al. 1997). It has
also been reported that IGF1 production in bone
microenvironment is more relevant to skeletal
maintenance than circulating IGF1 (Ohlsson et al.
2011; Yakar et al. 2002). Our finding of the
presence of low levels of gene expression of IGF
system within bone matrix in telomerase deficient
murine MSC corroborate the contribution of local
IGF system to impaired bone formation during
aging. On the other hand, mutant mice exhibiting
reduced GH/IGF1/insulin secretions exhibit
extended life span (Brown-Borg et al. 1996; Kurosu
et al. 2005). However, bone mass has not been
directly measured in these mice.
The role of IGF1 in cellular senescence is not
completely understood. Similar to our findings, age-
related decline in IGF1 and IGFBP3 has been reported
in mice and rats (Severgnini et al. 1999; Xian et al.
2012). Also, a recent study employing aged mice
reported that activation of cellular telomerase activity
delayed many aspects of age-related phenotypes and
improved longevity which was associated with
increased serum IGF1 levels (de Bernardes et al.
2012). The role of IGF1 in bone biology has been
demonstrated in IGF1-deficient mice that exhibited
skeletal malformation, delayed mineralization,
decreased chondrocyte proliferation and increased
chondrocyte apoptosis (Laviola et al. 2008). In human
conditions of bone loss, IGF1 action and signaling is
impaired in osteoblastic cells (Perrini et al. 2010).
Likewise, reduction in IGF1 levels has been reported
in age related bone loss, both men and women
(Boonen et al. 1999; Nicolas et al. 1994; Rosen et al.
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Fig. 5 Impaired IGF1-induced AKT phosphorylation in telom-
erase deficient murine marrow stromal cells (mMSCs). a Re-
ducedAKT and PDK1 phosphorylation following IGF1 (10 ng/mL)
treatment of Terc-/-mMSCs versus WT mMSCs. Western blot
analysis of phosphorylated and total p85, PTEN, PDK1 and
AKT as well as loading control a-Tubulin following 10 and
20 min of IGF1stimulation. Data are generated from pooled
protein samples from three independent experiments of IGF1–
stimulated Terc-/- mMSCs versus WT mMSC. Quantification
analysis of WB was performed by ImageJ. Data are mean ± SD
of three independent experiments. *p B 0.05, **p B 0.01
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of recombinant human IGF1 has been associated with
improved osteoblast functions in healthy females
exhibiting decreased bone turnover due to caloric
restrictions (Grinspoon et al. 1996). Interestingly,
PI3 K/AKT signaling is utilized by IGF1 to reduce
osteoblast apoptosis (Grey et al. 2003). Comparative
analysis of IGF signaling in human osteoblast cultures
established from healthy donors and osteoporotic
patients revealed that IGFR1 and components of
IGF1 downstream signaling were not responsive to
IGF1 stimulation in osteoporotic cells due to reduced
phosphorylation of AKT at Ser-473 and Thr-308
(Perrini et al. 2008). Furthermore, data from IGF1
conditional gain and loss of function studies in mice
employing osteoblast specific gene promoters, such as
Col1a1 and Col1a2, respectively, suggest that IGF1
gain of function resulted in increase length of long
bones and cortical width in mice while loss of function
resulted in decrease bone formation and bone mass
(Jiang et al. 2006). Similarly, Xian et al., demonstrated
that IGF1 stimulation activates mTOR via PI3K/AKT
pathway in Sca1?mMSCs and conditioned media
containing IGF1 released from bone matrix signifi-
cantly enhanced osteoblast differentiation and
increased phosphorylation of PI3K, AKT and mTOR
(Xian et al. 2012), implicating PI3K/AKT signaling in
mediating IGF1 effects on bone. Thus, the ability of
IGF1 to rescue aspects of age-related phenotype
requires further investigation.
In addition to changes in IGF1, we observed that the
levels of telomerase activity in MSC affected several
IGFBPs gene expression and serum levels. The
bioactivity of IGF1 is regulated by several IGF
binding proteins (IGFBPs) which mainly modulate
IGF1 bioavailability to IGF receptors (Muck et al.
2008). IGFBP3 is an abundant protein in human serum
and binds over 90 % of circulating IGF1 resulting in
prolonged half-life of IGF1 (Baxter and Martin 1989)
and the resulting IGF1/IGFBP3 complex exerts tissue
and cell type specific effects (Baege et al. 2004).
IGFBP3 has been shown to inhibit cell growth by
interfering with IGF1 interaction with its cognate
receptor (Kelley et al. 1996). IGFBP3 has also IGF1-
indpenent effects on cell growth (Firth and Baxter
2002). Increased expression of IGFBP3 has been
reported in senescent cells (Baege et al. 2004; Muck
et al. 2008) and has been proposed as a marker of
cellular senescence (Baege et al. 2004). Additionally,
we also observed increased in serum levels of IGFBP4
which is an inhibitory IGFBP (Kassem et al. 1996).
Thus, it is possible that the net effects are decreased
serum IGF1 bioactivity.
Conclusion
Our data suggest that telomerase activity regulates
IGF1 dependent PI3K/AKT signaling and that age-
related deficiency in telomerase activity in osteoblas-
tic cells contributes to age-related decreased bone
formation. Modulating osteoblastic cells telomerase
enzyme or IGF signaling activity pharmacologically is
a possible strategy for prevention of age related bone
loss.
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